OmniAb Investor Presentation Deck
Performance Indicators
ACTIVE CLINICAL PROGRAMS AND APPROVED PRODUCTS
• 2 new programs entered the clinic in Q2
- IMVT-1402 (Immunovant): Next-generation FcRn antagonist
GLS-012 (Gloria): anti-LAG-3
●
●
3 new programs have entered the clinic so far in the first half of 2023
Based on dialog with our partners, we see potential for 1-2
additional new entries into clinical development for novel OmniAb-
derived antibodies in the second half of 2023
Partner progression also showing the flexibility of our platform, with an
increasing number of formats and modalities in clinical or preclinical
development
30
25
20
15
10
5
Number of Active
Clinical Programs and
Approved Products
J
2016
2017
2018
2019
2020
2021
2022
6/30/2023
9
OmniAbView entire presentation